Terms: = Skin cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
493 results:
1. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
[TBL] [Abstract] [Full Text] [Related]
2. Effective Targeting of Melanoma Cells by Combination of mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
3. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
4. Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
[TBL] [Abstract] [Full Text] [Related]
5. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome.
Sánchez-Heras AB; Dámaso E; Castillejo A; Robledo M; Teulé A; Lázaro C; Sánchez-Martínez R; Zúñiga Á; López-Fernández A; Balmaña J; Robles L; Ramon Y Cajal T; Castillejo MI; Ibañez RP; Sevila CM; Sánchez-Mira A; Escandell I; Gómez L; Berbel P; Soto JL
Orphanet J Rare Dis; 2024 Jan; 19(1):26. PubMed ID: 38279137
[TBL] [Abstract] [Full Text] [Related]
6. Malignant glomus tumor arising in association with a fumarate hydratase-deficient leiomyoma: An unusual collision tumor.
Short EL; Logan SJ; Thangaiah JJ; Folpe AL
J Cutan Pathol; 2024 Apr; 51(4):272-275. PubMed ID: 38140939
[TBL] [Abstract] [Full Text] [Related]
7. Recurrent and metastatic cellular cutaneous fibrous histiocytoma: A case report and literature review.
Fuentes-Sánchez J; Pena-Burgos EM; Tapia-Viñe M; Ortiz-Cruz EJ; Pozo-Kreilinger JJ
J Cutan Pathol; 2024 Mar; 51(3):214-220. PubMed ID: 38084789
[TBL] [Abstract] [Full Text] [Related]
8. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract] [Full Text] [Related]
9. Secondary malignancies among mantle cell lymphoma patients.
Abalo KD; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Eur J Cancer; 2023 Dec; 195():113403. PubMed ID: 37952281
[TBL] [Abstract] [Full Text] [Related]
10. The Role of Morphology in Predicting Fumarate Hydratase-deficient Uterine Leiomyomas in Young Women.
Bayram A; Bagbudar S; Sozen H; Onder S; Yavuz E
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):657-660. PubMed ID: 37751278
[TBL] [Abstract] [Full Text] [Related]
11. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A; Petrillo A; Della Pia A; Lee GG; Gill S; Varughese T; Zenreich J; Gutierrez M; Zhang J; Ahn J; Bharani V; Nejad AS; Pascual L; Feldman TA; Leslie LA; Goy AH
Leuk Lymphoma; 2023 Dec; 64(14):2225-2235. PubMed ID: 37740588
[TBL] [Abstract] [Full Text] [Related]
12. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism.
Valcarcel-Jimenez L; Frezza C
Br J Cancer; 2023 Nov; 129(10):1546-1557. PubMed ID: 37689804
[TBL] [Abstract] [Full Text] [Related]
13. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
Yamshon S; Chen GZ; Gribbin C; Christos P; Shah B; Schuster SJ; Smith SM; Svoboda J; Furman RR; Leonard JP; Martin P; Ruan J
Blood Adv; 2023 Nov; 7(21):6579-6588. PubMed ID: 37682791
[TBL] [Abstract] [Full Text] [Related]
14. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract] [Full Text] [Related]
15. Henoch-Schonlein Purpura, an Unusual Presentation of Acute Myeloid Leukemia.
Butt MA; Aamer S; Kapetanos A
Anticancer Res; 2023 Aug; 43(8):3579-3582. PubMed ID: 37500160
[TBL] [Abstract] [Full Text] [Related]
16. Combined mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract] [Full Text] [Related]
17. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract] [Full Text] [Related]
18. CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling.
Ai C; Sun X; Xiao S; Guo L; Shang M; Shi D; Meng D; Zhao Y; Wang X; Li J
J Nanobiotechnology; 2023 Jul; 21(1):214. PubMed ID: 37420266
[TBL] [Abstract] [Full Text] [Related]
19. FOXA2 controls the anti-oxidant response in FH-deficient cells.
Rogerson C; Sciacovelli M; Maddalena LA; Pouikli A; Segarra-Mondejar M; Valcarcel-Jimenez L; Schmidt C; Yang M; Ivanova E; Kent J; Mora A; Cheeseman D; Carroll JS; Kelsey G; Frezza C
Cell Rep; 2023 Jul; 42(7):112751. PubMed ID: 37405921
[TBL] [Abstract] [Full Text] [Related]
20. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract] [Full Text] [Related]
[Next]
